The Labs I Actually Care About
I care most about labs that change prevention strategy: ApoB/lipids, A1c plus fasting glucose and sometimes insulin, kidney and liver function, CBC, thyroid when symptoms fit, iron/B12/vitamin D when risk fits, and targeted inflammatory or hormone testing when the question is real.
Default panel
ApoB/lipids, A1c/glucose, CBC/CMP, kidney markers, blood pressure, and selected urine testing.
Add by story
TSH, ferritin, B12, vitamin D, hsCRP, hormones, or autoimmune testing only when history gives them a job.
Repeat with intent
Retest the marker you are trying to change on a timeline that matches the biology.
My default prevention panel
A good lab panel is a decision tool. It should tell us what risk is present, what is changing, and whether a treatment is safe. It should not be a museum of biomarkers.
Diagram
The prevention-lab decision map
Start with tests that change risk management or safety monitoring. Add specialty markers only when the history gives them a job.
Baseline risk
ApoB/lipid panel, A1c or fasting glucose, blood pressure, and waist or body-composition context.
These answer the core prevention question: what risk needs active reduction?
Organ safety
CMP, creatinine/eGFR, electrolytes, liver enzymes, and CBC.
These help catch safety issues before medication, supplement, nutrition, or training changes.
Risk modifiers
Lp(a) once, urine albumin/creatinine when risk fits, and hsCRP selectively.
Use these when the result would change prevention intensity or follow-up.
Story-driven tests
TSH, ferritin/iron studies, B12, vitamin D, hormones, or autoimmune testing when symptoms or risk make the question real.
This is where over-testing usually sneaks in; the test needs a clinical job.
Follow-up marker
Repeat the marker the plan was designed to move, on a timeline that matches the biology.
A lab earns its place twice: first by changing the plan, then by showing whether the plan worked.
Protocol
Default versus story-driven testing
| Use case | Usually enough | Add only if it changes action |
|---|---|---|
| Prevention baseline | ApoB/lipids, A1c or glucose, BP, CMP, CBC | Lp(a), urine albumin, insulin, hsCRP, or CAC context when risk is unclear |
| Fatigue or low energy | CBC, CMP, TSH if symptoms fit | Ferritin/iron studies, B12, vitamin D, sleep or inflammatory workup based on story |
| Medication or supplement monitoring | Kidney/liver/electrolyte markers relevant to the intervention | Only the safety markers tied to the actual risk |
| After an intervention | The marker you were trying to improve | A wider panel only if side effects, new symptoms, or a new decision appears |
This is a decision framework, not a universal order set; pregnancy, symptoms, medications, and known disease change the panel.
Cardiometaboliclipid panel, ApoB, A1c, fasting glucose, blood pressure, waist or body composition.
Safety and organ functionCMP, creatinine/eGFR, liver enzymes, electrolytes, CBC.
Risk-context testsurine albumin/creatinine, hsCRP, Lp(a), TSH, ferritin/iron studies, B12, vitamin D when indicated.
Intervention follow-upthe same marker you were trying to change, on a timeline that matches the biology.
What I would not do
I would not repeat a hundred-marker panel every month because it feels proactive. I would not treat every mild abnormality like a diagnosis. And I would not use a biological-age score as a substitute for cardiometabolic risk management.
The doctor decision rule
Before ordering a test, I want to know: what result would reassure us, what result would change treatment, and what result would create noise? If no answer changes action, the test is probably not ready for prime time.
Clinical lens
How I’d decide
Use this section as a second pass after the main answer, not as homework before you know what the page is saying.
Who it’s for
Adults building a prevention baseline, people changing nutrition/exercise/medications, and anyone with cardiometabolic risk, fatigue, perimenopause symptoms, family history, or abnormal prior labs.
Who should skip it
People using broad cash-pay panels without a clinical question. More biomarkers can mean more false alarms, follow-up scans, and anxiety without better care.
Measure before / after
At minimum: blood pressure, waist or body composition, lipid panel plus ApoB, A1c, fasting glucose, CMP, CBC, kidney markers, urine albumin when risk fits, and selected thyroid/nutrient/inflammation tests based on history.
What I’d do first
Start with a boring, decision-grade panel. Add specialty biomarkers only when they answer a specific question: risk refinement, medication safety, unexplained symptoms, or whether an intervention worked.
What would change my mind
A lab earns its place if it changes a decision repeatedly and improves outcomes or safety. I downgrade it if it mostly creates expensive ambiguity.
Frequently Asked Questions
Are longevity lab panels worth it?
Sometimes, but only when the result changes a decision. A large panel with no action plan mostly creates noise, cost, and follow-up ambiguity.
How often should prevention labs be repeated?
It depends on the marker and the intervention. Medication changes may justify 6–12 week follow-up; stable prevention labs often do not need frequent repeats.
Which lab is most underrated?
ApoB is often underrated because it can clarify cardiovascular risk when LDL-C and the rest of the metabolic picture do not line up.
References & citations
Related Guides
Next step
Turn the guide into the right next decision.
If this page raised a real clinical question, start with the practice details. If you are still learning, get the weekly letter. If you are comparing tests, use the testing hub before buying another panel.